Pedro Freitas

7PUBLICATIONS
17CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNeurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 17, 2025
4K density: Adjusting the 4Kscore for prostate volume to improve risk stratification of clinically significant prostate cancer in men undergoing prostate biopsy.

Timothy Guerard, Joao G Porto, Thomas Fekete

|Jun 20, 2025
Can Genomic Classifiers in Biopsy Cores With Grade Group 1 Cancer Predict Higher-Grade Disease Elsewhere in the Prostate? Results From the Prospective Miami Active Surveillance Trial.

Pedro F S Freitas, Archan Khandekar, Joao G Porto

|Feb 22, 2025
Cabazitaxel versus abiraterone or enzalutamide for metastatic castration-resistant prostate cancer following docetaxel failure: a systematic review and meta-analysis.

Izael Pereira da Silva, Lucas Guimarães Campos Roriz de Amorim, Gabriel Vieira Piredda

|Nov 14, 2024
HSD3B1, prostate cancer mortality and modifiable outcomes.

Pedro F S Freitas, Alireza Abdshah, Rana R McKay

|Sep 30, 2024
Changing times: trends in risk classification, tumor upstaging, and positive surgical margins after radical prostatectomy - results from a contemporary National Cancer Database study.

Pedro F S Freitas, Ruben Blachman-Braun, Nachiketh Soodana-Prakash

|Mar 19, 2021
Severe urinary tract damage secondary to primary bladder neck obstruction in women.

Pedro F S Freitas, Augusto Q Coelho, Homero Bruschini

Pageof 2

Frequent Collaborators

2 joint publications

Oleksandr N Kryvenko

2 joint publications

Hui Yu

2 joint publications

Joao G Porto

1 joint publications

Chad Ritch